[Chemotherapy in advanced non small cell lung cancer]

Lung cancer is the worlds first cause of death by cancer. Locally advanced and metastatic non small cell cancers represent 2/3rd of cases at diagnosis and are of worst prognosis. We conducted a retrospective study of 202 patients to investigate the effect of chemotherapy on survival and quality of life. 95 patients received chemotherapy with VP16- CDDP [88%] or Gemcitabin-CDDP Improvement survival was observed in the chemotherapy group: 8 month IC 95% [6.6-9.3]4 month IC 95% [3.1-4.9] in the control group. Chemotherapy also had a good perfect on the quality of life with improvement of performance status symptoms and need of analgesic. However, although significant the role of chemotherapy in NSCLC remains modest and new therapeutic approaches are needed including prevention and early detection which are probably more effective and cheaper

Survie et facteurs pronostiques du carcinome bronchique non. a petites cellules: Revue analytique de 211 cas

Prognostic factors have a pivotal role in clinical oncology. They are helpful in the selection of treatment, provide insights into the disease process and the therapeutic response. The number of possibly useful prognostic factors in the lung cancer is large. This study attempts to observe the survival of non small cell lung cancer [NSCLC] and to find prognostic factors and other variables potentially associated with outcome of lung cancer. It's a retrospective study based on 211 patients with NSCLC. Median survival was 6 months with 95% confidence interval [4,2 - 7,8]. Overall 3 and 5 year survival were respectively 8,3% and 5,2%. Various Prognostic factors have been identified through univariate [Koplan-Meier] then multivariate [Cox] analyses. In addition to the clinical factors such as age, disease extent and performance status, other variables were found of significant prognostic value, like pre-therapeutic leukocyte level. Survival was significantly improved with surgery, radiation and also with chemotherapy, mainly in advanced. stage [IIIB and IV]